Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.37

0.235 (1.55%)

08:22
08/08/17
08/08
08:22
08/08/17
08:22

Valeant CFO says Salix business had 'very strong quarter'

Herendeen said Salix "had a very strong quarter, posting organic growth of 16%. We enjoyed improved net pricing in the Salix business as result of modest price increases across the GI portfolio as well as favorable gross-to-net items compared with the prior year quarter. While the improved net pricing is awesome, I just caution that part of that improvement is less durable than the rest. Also encouraging, Salix volume was up over the prior year quarter by some of 350 basis points, mainly driven by increased demand from XIFAXAN. We made considerable investments in the new Primary Care sales team, and we're starting to see measurable progress growing XIFAXAN prescriptions for IBS-D." In Q2, total prescriptions for XIFAXAN were up 2% while extended units, which means the total prescriptions multiplied by the bills for Rx, were up 4% compared with Q2 last year, he noted. Valeant CFO Paul Herendeen is speaking on the company's Q2 earnings call.

  • 08

    Aug

  • 24

    Aug

VRX Valeant
$15.37

0.235 (1.55%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.

TODAY'S FREE FLY STORIES

NKE

Nike

$73.94

-0.785 (-1.05%)

07:37
06/22/18
06/22
07:37
06/22/18
07:37
Downgrade
Nike rating change  »

Nike downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AYX

Alteryx

$38.63

-1.21 (-3.04%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Initiation
Alteryx initiated  »

Alteryx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALBO

Albireo Pharma

$36.05

1.05 (3.00%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Conference/Events
Albireo Pharma management to meet with Needham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

INTC

Intel

$52.19

-1.27 (-2.38%)

, JPM

JPMorgan

$107.52

-0.04 (-0.04%)

07:35
06/22/18
06/22
07:35
06/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

INTC

Intel

$52.19

-1.27 (-2.38%)

JPM

JPMorgan

$107.52

-0.04 (-0.04%)

MS

Morgan Stanley

$49.78

-0.095 (-0.19%)

PG

Procter & Gamble

$76.44

0.59 (0.78%)

LUV

Southwest

$53.15

1.16 (2.23%)

PAGS

PagSeguro Digital

$29.42

0.91 (3.19%)

COTY

Coty

$14.48

0.03 (0.21%)

HBI

Hanesbrands

$22.04

0.615 (2.87%)

SYK

Stryker

$169.81

0.21 (0.12%)

ECA

Encana

$12.19

-0.235 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 24

    Jul

  • 26

    Jul

  • 12

    Oct

  • 22

    Jun

SRPT

Sarepta

$149.57

-4.12 (-2.68%)

07:34
06/22/18
06/22
07:34
06/22/18
07:34
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.95

-0.12 (-11.22%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Syndicate
iBio raises $16M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$462.87

-2.66 (-0.57%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Periodicals
Chipotle will test new menu items, strategy, NY Times reports »

Chipotle is adding five…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

ABBV

AbbVie

$95.55

-2.72 (-2.77%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Recommendations
AbbVie analyst commentary  »

AbbVie most exposed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$198.83

-2.565 (-1.27%)

07:32
06/22/18
06/22
07:32
06/22/18
07:32
Conference/Events
Lear to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

, NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

07:31
06/22/18
06/22
07:31
06/22/18
07:31
Hot Stocks
Qualcomm extends cash offer for NXP Semiconductors to June 29 »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, RIG

Transocean

$11.94

-0.575 (-4.60%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

RIG

Transocean

$11.94

-0.575 (-4.60%)

CSX

CSX

$64.06

-0.81 (-1.25%)

Z

Zillow

$61.83

-2.84 (-4.39%)

KMB

Kimberly-Clark

$100.15

-1.51 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Williams Scotsman »

WillScot Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SENS

Senseonics

$4.96

0.1 (2.06%)

07:29
06/22/18
06/22
07:29
06/22/18
07:29
Recommendations
Senseonics analyst commentary  »

Senseonics FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAKE

Cheesecake Factory

$59.87

2.13 (3.69%)

07:28
06/22/18
06/22
07:28
06/22/18
07:28
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Conference/Events
Williams Scotsman to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SLNO

Soleno Therapeutics

$2.34

-0.02 (-0.85%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Initiation
Soleno Therapeutics initiated  »

Soleno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$91.53

-1.84 (-1.97%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$40.00

9.3 (30.29%)

07:25
06/22/18
06/22
07:25
06/22/18
07:25
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

KLAC

KLA-Tencor

$110.31

0.54 (0.49%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$165.62

-3.64 (-2.15%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CSCO

Cisco

$43.17

-0.58 (-1.33%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Cisco analyst commentary  »

Cisco selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 12

    Jul

TNDM

TNDM

, DXCM

DexCom

$99.72

-0.88 (-0.87%)

07:23
06/22/18
06/22
07:23
06/22/18
07:23
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes'…

TNDM

TNDM

DXCM

DexCom

$99.72

-0.88 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

DRI

Darden

$107.07

13.8 (14.80%)

07:22
06/22/18
06/22
07:22
06/22/18
07:22
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

VSLR

Vivint Solar

$5.00

-0.05 (-0.99%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Vivint Solar rating change  »

Vivint Solar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$55.70

-0.1 (-0.18%)

, CTWS

Connecticut Water

$66.53

0.28 (0.42%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Eversource, Connecticut Water rating change  »

Eversource upgraded to…

ES

Eversource

$55.70

-0.1 (-0.18%)

CTWS

Connecticut Water

$66.53

0.28 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.